Skip to main content
Erschienen in: International Journal of Clinical Oncology 2/2016

22.08.2015 | Original Article

The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients

verfasst von: Toshiro Masuda, Masafumi Kuramoto, Shinya Shimada, Satoshi Ikeshima, Kenichiro Yamamoto, Kenichi Nakamura, Shinich Yoshimatsu, Masayuki Urata, Hideo Baba

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to investigate the effects of extensive intraoperative peritoneal lavage (EIPL) therapy on stage III B + C and CY1/P0 gastric cancer patients after potentially curative surgery.

Methods

The study included 37 patients with CY1/P0 and 23 patients with stage III B + C gastric cancer who were treated with potentially curative gastrectomy and EIPL therapy between March 1995 and May 2013. D2 lymphadenectomy, R0 resection, and EIPL therapy were performed for all cases.

Results

Multivariate analysis revealed that male gender (P = 0.01) and lymph node metastasis (P = 0.03) were independent prognostic factors, while positive cytology was not (P = 0.21). There was no significant difference in overall survival rates between the CY1/P0 and stage III B + C groups (P = 0.93). There was also no significant difference in peritoneal recurrence rates, i.e., 13 (35.1%) in the CY1/P0 group and 5 (21.7%) in the stage III B + C group (P = 0.39).

Conclusions

EIPL therapy combined with complete resection and sufficient (D2) lymphadenectomy could improve the prognosis of CY1/P0 gastric cancer and, to a similar extent, that of stage III B + C.
Literatur
1.
Zurück zum Zitat Yonemura Y, Endou Y, Shinbo M et al (2009) Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 100:311–316CrossRefPubMed Yonemura Y, Endou Y, Shinbo M et al (2009) Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 100:311–316CrossRefPubMed
2.
3.
Zurück zum Zitat Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112CrossRef Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112CrossRef
4.
Zurück zum Zitat Sobin L, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley, New York Sobin L, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley, New York
5.
Zurück zum Zitat Leake PA, Cardoso R, Seevaratnam R et al (2012) A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 15(Suppl 1):S27–S37CrossRefPubMed Leake PA, Cardoso R, Seevaratnam R et al (2012) A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 15(Suppl 1):S27–S37CrossRefPubMed
6.
Zurück zum Zitat Mezhir JJ, Shah MA, Jacks LM et al (2010) Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 17:3173–3180CrossRefPubMed Mezhir JJ, Shah MA, Jacks LM et al (2010) Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 17:3173–3180CrossRefPubMed
7.
Zurück zum Zitat Marutsuka T, Shimada S, Shiomori K et al (2003) Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res 9:678–685PubMed Marutsuka T, Shimada S, Shiomori K et al (2003) Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res 9:678–685PubMed
8.
Zurück zum Zitat Shimada S, Tanaka E, Marutsuka T et al (2002) Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells. Gastric Cancer 5:168–172CrossRefPubMed Shimada S, Tanaka E, Marutsuka T et al (2002) Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells. Gastric Cancer 5:168–172CrossRefPubMed
9.
Zurück zum Zitat Yamamoto K, Shimada S, Hirota M et al (2005) EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. Int J Oncol 27:1321–1328PubMed Yamamoto K, Shimada S, Hirota M et al (2005) EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. Int J Oncol 27:1321–1328PubMed
10.
Zurück zum Zitat Ikeshima S, Kuramoto M, Shimada S et al (2013) Standard prophylactic strategy against peritoneal dissemination metastasis in gastric cancer. J Cancer Ther 4:99–103CrossRef Ikeshima S, Kuramoto M, Shimada S et al (2013) Standard prophylactic strategy against peritoneal dissemination metastasis in gastric cancer. J Cancer Ther 4:99–103CrossRef
11.
Zurück zum Zitat Kuramoto M, Shimada S, Ikeshima S et al (2012) A proposal of a practical and optimal prophylactic strategy for peritoneal recurrence. J Oncol 2012:340380CrossRefPubMedPubMedCentral Kuramoto M, Shimada S, Ikeshima S et al (2012) A proposal of a practical and optimal prophylactic strategy for peritoneal recurrence. J Oncol 2012:340380CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kuramoto M, Shimada S, Ikeshima S et al (2009) Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 250:242–246CrossRefPubMed Kuramoto M, Shimada S, Ikeshima S et al (2009) Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 250:242–246CrossRefPubMed
13.
Zurück zum Zitat Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1:10–24CrossRefPubMed Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1:10–24CrossRefPubMed
14.
Zurück zum Zitat Fujimoto S, Takahashi M, Mutou T et al (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884–891CrossRefPubMed Fujimoto S, Takahashi M, Mutou T et al (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884–891CrossRefPubMed
15.
Zurück zum Zitat Gunji S, Obama K, Matsui M et al (2013) A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin. Surgery 154:991–999CrossRefPubMed Gunji S, Obama K, Matsui M et al (2013) A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin. Surgery 154:991–999CrossRefPubMed
16.
Zurück zum Zitat Hall JJ, Loggie BW, Shen P et al (2004) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 8:454–463CrossRefPubMed Hall JJ, Loggie BW, Shen P et al (2004) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 8:454–463CrossRefPubMed
17.
Zurück zum Zitat Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefPubMed Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefPubMed
18.
Zurück zum Zitat Yu X, Ren Z, Xue Y et al (2013) D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer. Neoplasma 60:174–181CrossRefPubMed Yu X, Ren Z, Xue Y et al (2013) D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer. Neoplasma 60:174–181CrossRefPubMed
19.
Zurück zum Zitat Matharu G, Tucker O, Alderson D (2011) Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg 98:1225–1235CrossRefPubMed Matharu G, Tucker O, Alderson D (2011) Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg 98:1225–1235CrossRefPubMed
20.
Zurück zum Zitat Yan TD, Black D, Sugarbaker PH, Zhu J et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713CrossRefPubMed Yan TD, Black D, Sugarbaker PH, Zhu J et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713CrossRefPubMed
21.
Zurück zum Zitat Emoto S, Yamaguchi H, Kamei T et al (2013) Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today 44:919–926CrossRefPubMed Emoto S, Yamaguchi H, Kamei T et al (2013) Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today 44:919–926CrossRefPubMed
Metadaten
Titel
The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients
verfasst von
Toshiro Masuda
Masafumi Kuramoto
Shinya Shimada
Satoshi Ikeshima
Kenichiro Yamamoto
Kenichi Nakamura
Shinich Yoshimatsu
Masayuki Urata
Hideo Baba
Publikationsdatum
22.08.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0892-6

Weitere Artikel der Ausgabe 2/2016

International Journal of Clinical Oncology 2/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.